Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BI 770371 |
Synonyms | |
Therapy Description |
BI 770371 is a monoclonal antibody that targets SIRPa, potentially leading to increased antitumor immune response (Ann Oncol (2023) 34 (suppl_2): S485). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BI 770371 | BI770371|BI-770371 | BI 770371 is a monoclonal antibody that targets SIRPa, potentially leading to increased antitumor immune response (Ann Oncol (2023) 34 (suppl_2): S485). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05327946 | Phase I | BI 770371 BI 770371 + Ezabenlimab | A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated | Active, not recruiting | USA | CAN | 1 |